Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 11/20 | 0.58 |
| ▸ | PLD2 | O14939 | 1/20 | 0.41 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 6/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4758968 | 0.92 | AVPR1A (0.57) | AVPR1APLD2PLD1F11OXTR | |
| SCHEMBL4759784 | 0.92 | AVPR1A (0.59) | AVPR1APLD2PLD1F11OXTR | |
| SCHEMBL4758961 | 0.91 | AVPR1A (0.59) | AVPR1APLD2PLD1F11OXTR | |
| SCHEMBL4368459 | 0.89 | AVPR1A (0.55) | AVPR1ACNR1 | |
| SCHEMBL4760560 | 0.88 | AVPR1A (0.65) | AVPR1AF11OXTRCNR1 | |
| SCHEMBL4814755 | 0.88 | AVPR1A (0.65) | AVPR1AF11OXTRCNR1 | |
| SCHEMBL14222624 | 0.85 | AVPR1A (0.45) | AVPR1APLD2PLD1F11 | |
| SCHEMBL4759236 | 0.85 | AVPR1A (0.58) | AVPR1AF11OXTRCNR1 | |
| SCHEMBL4811969 | 0.85 | AVPR1A (0.72) | AVPR1APLD2PLD1F11OXTR | |
| SCHEMBL4759148 | 0.85 | AVPR1A (0.61) | AVPR1AOXTRCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973913-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-10-01 | — | — | EP | claimed |
| US-7351706-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-01 | — | — | US | claimed |
| WO-2007077122-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | WO | claimed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | claimed |
| EP-1973913-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-7351706-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351706-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2007077122-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007077122-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | AVPR2, OXTR, AVPR1A | AVPR1A 3/4885PLD2 1763/4885PLD1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.